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This article contains data on the associations between ﬁxed and
modiﬁable host characteristics and twenty-three biomarkers of
inﬂammation and immune activation measured longitudinally in a
cohort of 250 HIV-uninfected men from the Multicenter AIDS
Cohort Study (1984–2009) after adjusting for age, study site, and
blood draw time of day using generalized gamma regression. This
article also presents associations between each biomarker and
each host characteristic in a sample restricted to 2001–2009. These
data are supplemental to our original research article entitled
“Host factors associated with serologic inﬂammatory markers
assessed using multiplex assays” (McKay, S. Heather, Bream, H. Jay,
Margolick, B. Joseph, Martínez-Maza, Otoniel, Phair, P. John,
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access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Epidemiology, immunology
ore speciﬁc sub-
ject areaCytokines, Chemokinesype of data Graphs, Heatmap
ow data was
acquiredTwo electrochemiluminesence-based multiplex assay panels (Proinﬂammatory
9-plex and Chemokine 7-plex; Meso-Scale Diagnostics, LLC, Rockville, MD) were used
to determine concentrations of IL-1β, IL-2, IL-6, IL-10, IL-12p70, GM-CSF, IFN-γ, TNF-α,
CXCL8, CXCL10, CCL11, CCL2, CCL13, CCL4, and CCL17. Concentrations of sCD14,
sgp130, sIL-2Rα, sTNF-R2, BAFF, sCD27, and CXCL13 were measured in a single panel
(Human Biomarker Custom Premix Kit A) using the ﬂuorescent bead-based multi-
plexed Luminex xMAP system at a centralized laboratory (Fluorokines MAP, R&D
Systems, Minneapolis, MN), and a Bio-Plex 200 Luminex instrument and Bio-
Plex software (Bio-Rad, Hercules, CA). CRP was measured at Quest Diagnostics
using a high-sensitivity nephelometric assay (Dade Behring, Inc., Newark, DE).ata format Analyzed
xperimental
factorsBlood was collected at each study visit. Serum samples were processed within
6 hours of blood draw and frozen at 80 °C. Prior to testing, a previously
unthawed stock vial was thawed for each study visit, aliquoted and refrozen at
80 °C until testing.xperimental
featuresSpecimens and data were collected from a cohort study; up to 4 visits per HIV-
uninfected participant were randomly selected from individuals across the span of the
study duration 1984–2009. All men with chronic HCV infection were included.ata source
locationLos Angeles, CA; Chicago, IL; Pittsburgh, PA; Washington, DC/Baltimore, MD, USAata accessibility Data is within this articleValue of the data
 These data provide previously unreported associations of a broad panel of serological inﬂammatory
biomarker measurements with ﬁxed and modiﬁable host factors in a large well-characterized cohort.
 The data provided here show the associations of host characteristics with these inﬂammatory
biomarkers with minimal adjustment for other covariates.
 Provide estimates of association between host sociodemographics and risk behaviors with each
inﬂammatory biomarker adjusting for co-morbidities using a dataset without missing morbidity
data (restricted to participants with complete morbidity information collected 2001–2009) for
comparison with the dataset that is not restricted to participants with co-morbidity information
(1984–2009).
 Host factors that are associated with individual inﬂammatory biomarkers may be potential con-
founders which have implications for the design and analysis of future epidemiologic studies that
seek to explore inﬂammatory pathways in disease pathogenesis.
 May stimulate further validation research on the relationship between these inﬂammatory bio-
markers and host characteristics in independent populations.
 May provide insight into inﬂammatory disease mechanisms that can be used to identify ther-
apeutic targets and modiﬁable factors, such as risk behaviors and chronic conditions.
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This data article is referred to in the research article entitled Host factors associated with serologic
inﬂammatory markers assessed using multiplex assays [1]. We present the percent differences in dis-
tributions of biomarkers of inﬂammation and immune activation associated with ﬁxed and modiﬁ-
able host characteristics, minimally-adjusted for age, blood draw time of day, and study site, using
serum specimens measured longitudinally (1984–2009) from a sample of HIV-uninfected men in the
Multicenter Center AIDS Cohort Study (MACS). Multivariate associations between these biomarkers
and sociodemographics and risk behaviors in a sample restricted to 2001–2009 and additionally
adjusted for select co-morbidities were also examined.2. Experimental design, materials and methods
The MACS has been previously described; brieﬂy, it is a longstanding, prospective cohort study of
men who sex with men (MSM) enrolled at four U.S. locations (Baltimore/Washington D.C., Chicago,
Los Angeles, and Pittsburgh) to examine the natural and treated histories of HIV-1 infection [2,3].
Study highlights, including data collection forms, may be found at https://statepi.jhsph.edu/macs/
macs.html.
Fig. 1. (A) Percent difference estimates for a 10-year difference in age for each biomarker, adjusted for MACS study site and time of day
of blood draw. Blue circles represent the percent difference in biomarker concentrations for a 10-year difference in age. For example, a
percent difference of 18 for CXCL10 indicates that a 10-year increase in age is associated with 18% higher concentrations of CXCL10. The
red line indicates unity, i.e., no relative difference in biomarker concentrations. Filled markers represent statistical signiﬁcance
(Po0.002). (B) Percent difference estimates in biomarker concentrations for non-blacks vs. blacks, adjusted for age, MACS study site,
and time of day of blood draw. Blue circles represent the percent difference in biomarker concentrations for non-blacks relative to
blacks. The red line indicates unity, i.e., no relative difference in biomarker concentrations. Filled markers represent statistical sig-
niﬁcance (Po0.002). (C) Percent difference estimates in biomarker concentrations for overweight BMI vs. normal BMI, adjusted for age,
MACS study site, and time of day of blood draw. Blue circles represent the percent difference in each biomarker concentration between
men with overweight BMI relative to men with normal BMI. The red line indicates unity, i.e., no relative difference in biomarker
concentrations. Filled markers represent statistical signiﬁcance (Po0.002). (D) Percent difference estimates in biomarker concentra-
tions for obese BMI vs. normal BMI, adjusted for age, MACS study site, and time of day of blood draw. Blue circles represent the percent
difference in biomarker concentrations for men with obese BMI relative to men with normal BMI. The red line indicates unity, i.e., no
relative difference in biomarker concentrations. Filled markers represent statistical signiﬁcance (Po0.002). (E) Percent difference
estimates in biomarker concentrations for thosewith cleared hepatitis C infection (antibodyþ only) vs. thosewho are not infectedwith
hepatitis C, adjusted for age, MACS study site, and time of day of blood draw. Blue circles represent the percent difference in biomarker
concentrations for menwith cleared hepatitis C infection (antibody þ only) relative to those without hepatitis C infection. The red line
indicates unity, i.e., no relative difference in biomarker concentrations. Filled markers represent statistical signiﬁcance (Po0.002).
(F) Percent difference estimates in biomarker concentrations for those with chronic hepatitis C infection vs. those who are not infected
with hepatitis C, adjusted for age, MACS study site, and time of day of blood draw. Blue circles represent the percent difference in
biomarker concentrations for men with chronic HCV relative to those without HCV. The red line indicates unity, i.e., no relative
difference in biomarker concentrations. Filled markers represent statistical signiﬁcance (Po0.002). (G) Percent difference estimates in
biomarker concentrations for former smokers vs. never smokers, adjusted for age, MACS study site, and time of day of blood draw. Blue
circles represent the percent difference in biomarker concentrations for former smokers relative to never smokers. The red line
indicates unity, i.e., no relative difference in biomarker concentrations. Filled markers represent statistical signiﬁcance (Po0.002).
(H) Percent difference estimates in biomarker concentrations for current smokers vs. never smokers, adjusted for age, MACS study site,
and time of day of blood draw. Blue circles represent the percent difference in biomarker concentrations for current smokers relative to
never smokers. The red line indicates unity, i.e., no relative difference in biomarker concentrations. Filled markers represent statistical
signiﬁcance (Po0.002). (I) Percent difference estimates in biomarker concentrations for moderate-heavy alcohol consumption vs. no
alcohol consumption since last visit, adjusted for age, MACS study site, and time of day of blood draw. Blue circles represent the percent
difference in biomarker concentration for moderate-heavy alcohol consumption relative to no alcohol consumption. The red line
indicates unity, i.e., no relative difference in biomarker concentrations. Filled markers represent statistical signiﬁcance (Po0.002).
(J) Percent difference estimates in biomarker concentrations for binge alcohol consumption vs. no alcohol consumption since last visit,
adjusted for age, MACS study site, and time of day of blood draw. Blue circles represent the percent difference in biomarker con-
centration for binge alcohol consumption relative to no alcohol consumption. The red line indicates unity, i.e., no relative difference in
biomarker concentrations. Filled markers represent statistical signiﬁcance (Po0.002). (K) Percent difference estimates in biomarker
concentrations for marijuana use vs. no marijuana use since last visit, adjusted for age, MACS study site, and time of day of blood draw.
Blue circles represent the percent difference in biomarker concentration for use of marijuana vs. no use of marijuana. The red line
indicates unity, i.e., no relative difference in biomarker concentrations. Filled markers represent statistical signiﬁcance (Po0.002).
(L) Percent difference estimates in biomarker concentrations for use of amyl nitrates vs. no use of amyl nitrates since last visit, adjusted
for age, MACS study site, and time of day of blood draw. Blue circles represent the percent difference in biomarker concentrations for
use of amyl nitrates relative to no use of amyl nitrates. The red line indicates unity, i.e., no relative difference in biomarker con-
centrations. Filled markers represent statistical signiﬁcance (Po0.002). (M) Percent difference estimates in biomarker concentrations
for use of stimulants vs. no use of stimulants since last visit, adjusted for age, MACS study site, and time of day of blood draw. Blue
circles represent the percent difference in biomarker concentration for use of stimulants relative to no use of stimulants. The red line
indicates unity, i.e., no relative difference in biomarker concentrations. Filled markers represent statistical signiﬁcance (Po0.002).
(N) Percent difference estimates in biomarker concentrations for depressive symptoms, adjusted for age, MACS study site, and time of
day of blood draw. Blue circles represent the percent difference in biomarker concentrations for presence of depressive symptoms
(CES-D Z 16 only) relative to no presence of depressive symptoms. The red line indicates unity, i.e., no relative difference in biomarker
concentrations. Filled markers represent statistical signiﬁcance (Po0.002). (O) Percent difference estimates in biomarker concentra-
tions for depression, adjusted for age, MACS study site, and time of day of blood draw. Blue circles represent the percent difference in
biomarker concentrations for depression (CES-DZ16 or self-reported use of depression medication) relative to no depression. The red
line indicates unity, i.e., no relative difference in biomarker concentrations. Filled markers represent statistical signiﬁcance (Po0.002).
(P) Percent difference estimates in biomarker concentrations for persistent diabetes, adjusted for age, MACS study site, and time of day
of blood draw. Blue circles represent the percent difference in biomarker concentrations for men with persistent diabetes relative to
those without persistent diabetes. The red line indicates unity, i.e., no relative difference in biomarker concentrations. Filled markers
represent statistical signiﬁcance (Po0.002). (Q) Percent difference estimates in biomarker concentrations for persistent hypertension,
adjusted for age, MACS study site, and time of day of blood draw. Blue circles represent the percent difference in biomarker con-
centrations for menwith persistent hypertension relative to those without persistent hypertension. The red line indicates unity, i.e., no
relative difference in biomarker concentrations. Filled markers represent statistical signiﬁcance (Po0.002). (R) Percent difference
estimates in biomarker concentrations for hypercholesterolemia, adjusted for age, MACS study site, and time of day of blood draw. Blue
circles represent the percent difference in biomarker concentration for men with hypercholesterolemia relative to men without
hypercholesterolemia. The red line indicates unity, i.e., no relative difference in biomarker concentrations. Filled markers represent
statistical signiﬁcance (Po0.002) (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web
version of this article).
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Fig. 1. (continued)
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Concentrations of 23 biomarkers of immune activation and inﬂammation (IL-1β, IL-2, IL-6, IL-10,
IL-12p70, GM-CSF, IFN-γ, TNF-α, CXCL8, CXCL10, CCL11, CCL2, CCL13, CCL4, CCL17, sCD14, sgp130, sIL-
2Rα, sTNF-R2, BAFF, and CXCL13) in archived serum specimens acquired longitudinally from 250
consenting HIV uninfected men, were obtained using two multiplex assay platforms. One additional
biomarker, C-reactive protein (CRP), was measured at Quest Diagnostics (Dade Behring, Inc., Newark,
DE) using a high-sensitivity immunonephelometric assay. All specimens for any given individual were
tested on the same plate to minimize variability. A description of the study sample selection has been
provided in our related research article [1]. Serum concentrations of IL-1β, IL-2, IL-6, IL-10, IL-12p70,
IFN-ɣ, GM-CSF, TNF-α, CCL11, CXCL8, CXCL10 , CCL2, CCL13, CCL4, and CCL17 were quantitated using
the Meso-Scale Discovery electrochemiluminescence-based platform (MSD; Meso-Scale Diagnostics,
LLC, Rockville, MD), while concentrations of sCD14, sgp130, sIL-2Rα, sTNF-R2, BAFF, sCD27, and
CXCL13 were obtained using the multiplexed Luminex xMAP system (Fluorokine
s
MAP) using assays
produced by R & D systems (Minneapolis, MN) and a Bio-Plex 200 Luminex instrument and Bio-Plex
software (Bio-Rad, Hercules, CA), as described previously [1].
Fig. 1. (continued)
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The exposures of interest in the present study include sociodemographic characteristics [age at
visit, race (non-black vs. black), baseline educational level (four-year college degree or higher vs. less
than college degree), and body-mass index (BMI¼weight (kg)/height (m)2; categorized as r24.9
(normal/underweight), 25–29.9 (overweight), and Z30 (obese))], behavioral risk factors [smoking
status (never, former, current), alcohol consumption (binge-heavy drinking [Z5 drinks/day at least
once a month], moderate-heavy [3–4 drinks/day more than once a month, or Z5 drinks/day less than
once a month], low-moderate [1–2 drinks/day or 3–4 drinks/day no more than once a month], or
none), and use of recreational drugs (marijuana, amyl nitrates, or any stimulant [cocaine, ecstasy,
methamphetamines, or any other uppers]), hepatitis C infection (HCV) (negative, cleared [antibodyþ
only], or chronic [RNA positive]), presence of depressive symptoms (Z16 on the Center for Epide-
miologic Studies Depression Scale (CES-D) [4]), and an expanded categorization of depressive
symptoms which additionally included men who reported using medication for depression since the
last visit, regardless of their CES-D score. Persistent diabetes (fasting glucoseZ126 mg/dl or diabetic
medication use), persistent hypertension (systolic blood pressure (SBP) Z140 mmHg, diastolic (DBP)
Z90 mmHg, or antihypertensive medication use) were deﬁned if present at Z2 visits prior to blood
H.S. McKay et al. / Data in Brief 9 (2016) 262–270268draw. Hypercholesterolemia was present if fasting total serum cholesterol was Z200 mg/dl. Blood
draw time of day was P.M. vs. A.M.
2.3. Statistical analysis
Generalized gamma regression models were conducted for each biomarker to examine differences
in concentrations according to categories of host characteristics described above. The generalized
gamma distribution is a ﬂexible three-parameter distribution that allows us to avoid making strong
assumptions regarding the distributions of different biomarkers [5]. Biomarker concentrations were
inversed so that measurements below the lower limit of detection could be handled as right-
censored. In all models, only the location (β) parameter was allowed to vary by exposure category,
while scale (σ) and shape (λ) were held constant. Relative percentiles (the exponential of the –β, to
account for using the inverse value) in biomarker concentrations were calculated for each covariate
category. Relative percentiles are presented as the percent difference in biomarker concentrations
between the exposed and unexposed [(relative percentile1) X 100]. For example, a percent dif-
ference of 50 indicates that an exposure was associated with a 50% reduction in the concentration
of the biomarker compared to the unexposed. Because σ and λ were held constant, the relativeFig. 2. Percent differences from multivariate generalized gamma regression models examining the associations of age (10-
year), non-black race, college education at baseline, blood draw time of day (P.M. versus A.M.), being overweight, obesity,
cleared (antibody þ only) hepatitis C infection (HCV), chronic hepatitis C infection, former smoking, current smoking, mod-
erate-heavy alcohol consumption, binge alcohol consumption, use of marijuana, use of amyl nitrates, use of stimulants, the
presence of depressive symptoms, and depression including those taking depression medication (column headings) with
individual biomarkers (row headings), adjusting for persistent diabetes, persistent hypertension, and hypercholesterolemia, in a
sample restricted to 2001–2009. Large bold text with black-bordered cells indicates signiﬁcance at the Po0.002 level; large
bold text without borders indicates marginal signiﬁcance (0.002oPr0.05). The color gradient of each cell illustrates the
magnitude of the estimate (darker red indicating stronger positive percent difference and darker blue indicating stronger
negative percent difference). For example, chronic HCV is associated with 64% higher concentrations of IL-10 (Po0.002) and
19% lower concentrations of CCL11 (0.002oPr0.05).
H.S. McKay et al. / Data in Brief 9 (2016) 262–270 269percentile comparing one exposure category to another is constant across percentiles of each bio-
marker. Robust standard errors were adjusted for repeated measurements by using the vce(cluster)
option in Stata. Age was centered at the median across all person-visits (46 years) and associations
per 10-years were assessed.
Fig. 1 shows the estimated percent differences in each biomarker by host characteristic exposure
status, minimally-adjusted for age, study site, and blood draw time of day and the full sample of
person-visits (1984–2009).
Fig. 2 shows the estimated associations between host characteristics and each biomarker from
models fully-adjusted for all sociodemographics and risk behaviors, and the select morbidities
(persistent diabetes, persistent hypertension, and hypercholesterolemia) in a sample restricted to
2001–2009, when consistent ascertainment of data on these morbidities began in the MACS. The
estimated percent differences in Fig. 2 are presented in the form of a heatmap, which allows
examination of the associations between individual characteristics with each biomarker as well as
examining the biomarkers that are associated with each exposure. Color densities for the heatmap are
standardized using the sample standard deviation of each exposure.
All statistical tests were 2-sided. To account for multiple testing, a Bonferroni adjustment at an α-
level of 0.05 [(0.05/23)¼0.002] for statistical signiﬁcance was employed. Estimates with
0.002oPr0.05 were considered marginally signiﬁcant.
Data were analyzed using SAS, version 9.3 (SAS Institute, Inc., Cary, North Carolina) and Stata,
version 13 (College Station, Texas).Acknowledgements
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